Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project – a collaborative study of hepatitis B-related liver disease in West Africa by Howell, Jessica et al.
EDITORIAL
185       March 2015, Vol. 105, No. 3
Hepatitis B and hepato­
cellular carcinoma in sub­
Saharan Africa (SSA)
Hepatitis B virus (HBV) infection causes a spectrum 
of acute and chronic liver disease ranging from 
inactive chronic carrier status to progressive chronic hepatitis, 
culminating in end-stage cirrhosis and liver cancer.[1] In SSA, HBV 
infection is endemic and the HBV-related disease burden is high. 
The lifetime risk of HBV infection is over 60%, and more than 8% 
of the population remain chronic HBV carriers who are at risk of 
progressive liver disease and HBV-related hepatocellular carcinoma 
(HCC). SSA has one of the highest HBV-related liver cancer rates 
in the world,[2] and it is the most common cancer among males 
and third most common among females.[3,4] Unfortunately, HCC is 
usually a highly aggressive tumour with limited treatment options, 
particularly in resource-poor settings such as SSA.[5] Furthermore, 
HBV-related HCC affects patients in their working and reproductive 
years.[5] HBV therefore represents a threat to health on the African 
continent.
Early detection and treatment of HBV infection reduces HCC 
incidence and mortality (primary prevention).[6,7] Furthermore, HCC 
survival is improved by early detection of potentially treatable 
HCC by screening of patients at risk.[8] However, limited access to 
affordable medical care is a major limiting factor in hepatitis and liver 
cancer management in SSA. Routine HBV and HCC screening and 
surveillance programmes for the general population are virtually non-
existent, and there is a lack of infrastructure to support channelling of 
screened patients into long-term treatment programmes.[9]
Safe and effective treatments for HBV exist, but in SSA treatment 
access is severely limited. Despite highly effective nucleoside 
analogues such as tenofovir being available in most countries in SSA 
at a generic price for the treatment of HIV infection, very few African 
countries offer publicly funded HBV treatment.[9]
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liver fibrosis and cancer in Africa:  
The PROLIFICA study
Against this sombre backdrop of HBV-related liver disease in SSA, 
the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) 
project was established in 2011 to address some of the urgent HBV 
research needs in West Africa. This is an ongoing 5-year translational 
research project funded by the European Union Framework 7[10] and 
represents a collaboration between Imperial College, London; the 
Medical Research Council (The Gambia Unit) in Fajara, The Gambia; 
the International Agency for Research on Cancer, Lyon, France; Le 
Dantec University Hospital, Dakar, and University of Thiès, Sénégal; 
and Jos University Teaching Hospital, Jos, Nigeria.
The overall aim of the project is to reduce the incidence of HBV-
related HCC in West Africa. The three specific aims of the project 
are demonstrating the feasibility of widespread screening for HBV-
related liver disease; establishing whether treatment of HBV with 
nucleoside analogues is a cost-effective method to reduce the burden 
of HBV-related liver disease and liver cancer in West Africa; and 
developing novel biomarkers to predict and diagnose HBV-related 
liver fibrosis and HCC.
Achievements of the PROLIFICA 
project so far
To date, the PROLIFICA study has provided important insights into 
HBV-related HCC in West Africa, including identification of novel 
metabonomic biomarkers that may prove useful for HCC diagnosis 
in resource-poor settings;[11,12] identification of genomic determinants 
of HCC and epidemiological insights into risks for more severe HBV-
related liver disease;[13] validation of point-of-care tests for HBV 
(manuscript in submission) and the optimal use of the Fibroscan 
to measure liver stiffness[14] as a surrogate imaging marker for liver 
fibrosis; and the non-invasive aspartate aminotransferase-to-platelet 
ratio (APRI score) to determine the severity of liver cirrhosis from 
simple blood tests (manuscript in submission).
Importantly, the PROLIFICA platform has resulted in crucial 
capacity building in each of the three countries involved in the study. 
Local health infrastructure has benefited from new technologies, 
such as the Fibroscan to assess liver fibrosis using ultrasound-based 
transient elastography, a mass spectroscopy system in The Gambia 
for local biomarker research and the development of in-house 
laboratory assays, as well as skills transference to build capacity for 
improved liver cancer healthcare in West Africa.
Local nursing, medical and laboratory staff have benefited from 
training, education and employment opportunities. Procedures and 
training in effective and secure data management and ethical research 
practices have also been a central part of the PROLIFICA platform. 
Local researchers have availed themselves of specialised academic 
mentorship at each of the three sites involved in the study to obtain 
higher research degrees and produce highly regarded academic 
publications. Finally, community education on HBV infection, mode 
of transmission and prevention is likely to have had a positive impact 
on HBV awareness, both at the community and political level.
Above all, the PROLIFICA platform has facilitated the development 
of strong relationships for future research collaborations and a deeper 
understanding of the barriers to improved healthcare delivery in 
Africa. All centres have benefited equally from the experience and 
knowledge shared between the investigating teams. Arguably these are 
the greatest achievements of the project. International collaborative 
projects between academic institutions in Africa and the rest of the 
world are a fantastic opportunity to share ideas, specialised expertise 
and new technologies and foster a united approach to solving some of 
the greatest public health challenges in Africa today. Collaborations 
also provide a stronger international voice to raise global awareness 
of the importance of liver disease in Africa among governments, the 
pharmaceutical industry and the international community.
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